Published in Am Health Drug Benefits on July 01, 2012
Disentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered care. J Behav Med (2014) 0.82
A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus. Stat Med (2015) 0.77
Heterogeneous depression trajectories in multiple sclerosis patients. Mult Scler Relat Disord (2016) 0.75
Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55
Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA (1995) 11.68
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res (2007) 4.01
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov (2007) 3.77
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA (1999) 3.07
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe. J Med Internet Res (2011) 2.19
Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci (2010) 2.06
Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer (2008) 1.77
Individual differences in quality-of-life treatment response. Med Care (2002) 1.64
Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res (2010) 1.61
Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J (2012) 1.60
A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value Health (2004) 1.49
Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res (2011) 1.43
Evaluating the statistical significance of health-related quality-of-life change in individual patients. Eval Health Prof (2005) 1.27
Prospective medicine: the role for genomics in personalized health planning. Pharmacogenomics (2004) 1.16
Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev (2007) 1.15
Interpreting and reporting results based on patient-reported outcomes. Value Health (2007) 1.12
Patient-reported outcomes and the mandate of measurement. Qual Life Res (2008) 1.09
Analysis and interpretation of results based on patient-reported outcomes. Value Health (2007) 1.04
The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet (2009) 1.03
Genetic and environmental influences on psychological distress in the population: General Health Questionnaire analyses in UK twins. Psychol Med (2003) 1.03
Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health (2009) 1.03
Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys (2010) 1.02
Heritability of self-reported health. Health Serv Res (2000) 1.00
Health span or life span: the role of patient-reported outcomes in informing health policy. Health Policy (2010) 0.87
Biological pathways and genetic variables involved in pain. Qual Life Res (2010) 0.87
Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol (2009) 0.85
The Generation R study: a candidate gene study and genome-wide association study (GWAS) on health-related quality of life (HRQOL) of mothers and young children. Qual Life Res (2010) 0.84
A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis (2009) 0.83
A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus. Clin Ther (2011) 0.83
Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health (2012) 0.82
Adaptive design clinical trials: Methodology, challenges and prospect. Indian J Pharmacol (2010) 0.82
Some statistical issues in microarray gene expression data. Radiat Res (2006) 0.80
Mathematical modeling of molecular data in translational medicine: theoretical considerations. Sci Transl Med (2010) 0.78